Myocardial gene expression in dilated cardiomyopathy treated with beta-blocking agents

Area of Science:

• Cardiology
• Molecular Biology
• Pharmacology

Background:

• Idiopathic dilated cardiomyopathy (IDC) is a condition affecting heart muscle function.
• Beta-blocker therapy is a potential treatment for improving cardiac function in IDC patients.
• The study investigates if beta-blockers alter myocardial gene expression related to contractility and hypertrophy.

Purpose of the Study:

• To test if beta-blocker therapy improves cardiac function in IDC by altering myocardial gene expression.
• To identify specific genes involved in contractility and pathologic hypertrophy that are affected by beta-blockers.
• To correlate changes in gene expression with improvements in left ventricular ejection fraction.

Main Methods:

• Randomized controlled trial involving 53 IDC patients assigned to beta-blockers (metoprolol or carvedilol) or placebo.
• Quantitative reverse-transcription polymerase chain reaction (RT-PCR) used to measure mRNA levels of key genes in endomyocardial biopsy samples.
• Genes analyzed included those for adrenergic receptors, calcium ATPase, and myosin heavy chains; beta-adrenergic receptor protein levels were also measured.
• Left ventricular ejection fraction (LVEF) assessed via radionuclide ventriculography at baseline and after six months.

Main Results:

• A significant improvement in LVEF (mean increase of 18.8 EF units) was observed in 26 of 32 beta-blocker-treated patients.
• Responders showed increased sarcoplasmic-reticulum calcium ATPase mRNA and alpha-myosin heavy chain mRNA, and decreased beta-myosin heavy chain mRNA.
• These gene expression changes were not observed in non-responders or in the placebo group with spontaneous improvement.
• No significant differences in beta-adrenergic receptor mRNA or protein expression changes were found between responders and non-responders.

Conclusions:

• Functional improvement in idiopathic dilated cardiomyopathy treated with beta-blockers is linked to specific alterations in myocardial gene expression.
• Changes in genes regulating calcium handling and myosin isoforms appear crucial for the beneficial effects of beta-blockers in IDC.
• This study provides molecular insights into the mechanism of beta-blocker action in dilated cardiomyopathy.